Non-invasive prenatal testing providing safe, accurate chromosomal analysis to support informed decisions throughout the pregnancy journey. Results in as little as 5 working days.
Irene NIPT uses cell-free fetal DNA (cffDNA) analysis from a simple maternal blood draw to screen for chromosomal abnormalities during pregnancy. Unlike invasive procedures such as amniocentesis, Irene NIPT carries no risk to the fetus while delivering highly accurate results.
Recommended from as early as 10 weeks of gestation, Irene NIPT is the preferred prenatal screening solution for leading hospitals and obstetricians throughout Thailand.
Detection of an extra copy of chromosome 21, the most common chromosomal abnormality. 99.9% detection rate.
Edwards syndrome (T18) and Patau syndrome (T13) screening with high sensitivity and specificity.
Detection of Turner syndrome (45X), Klinefelter syndrome (47XXY), and other sex chromosome conditions.
Optional enhanced panel for DiGeorge syndrome, Prader-Willi, Angelman, and other microdeletion conditions.
Optional gender determination available from 10 weeks gestation with high accuracy.
Easy-to-understand reports designed for both clinicians and patients, with risk scores and clear recommendations.
| Technology | Massively parallel sequencing (MPS) of cell-free fetal DNA |
| Sample Required | 10 mL maternal peripheral blood (EDTA tube) |
| Gestational Age | From 10 weeks (singleton and twin pregnancies) |
| Turnaround Time | 5 working days from sample receipt |
| Detection Rate T21 | >99.9% (sensitivity), >99.9% (specificity) |
| Detection Rate T18/T13 | >98% sensitivity |
| Fetal Fraction Minimum | 4% (automatic QC check) |
| Report Language | English and Thai |
| Laboratory Accreditation | ISO 15189, CAP |